Thrivent Financial for Lutherans Sells 7,410 Shares of Charles River Laboratories International, Inc. $CRL

Thrivent Financial for Lutherans lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 33.4% in the third quarter, Holdings Channel reports. The fund owned 14,766 shares of the medical research company’s stock after selling 7,410 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Charles River Laboratories International were worth $2,310,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Ariel Investments LLC grew its holdings in shares of Charles River Laboratories International by 28.6% during the 2nd quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after purchasing an additional 314,572 shares during the last quarter. Invesco Ltd. boosted its position in Charles River Laboratories International by 11.6% in the second quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock valued at $187,712,000 after buying an additional 128,785 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Charles River Laboratories International by 29.2% during the second quarter. Bank of America Corp DE now owns 1,026,013 shares of the medical research company’s stock worth $155,677,000 after buying an additional 232,020 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Charles River Laboratories International by 5.9% during the second quarter. Sei Investments Co. now owns 714,688 shares of the medical research company’s stock worth $108,440,000 after buying an additional 39,959 shares in the last quarter. Finally, Cooke & Bieler LP increased its holdings in shares of Charles River Laboratories International by 0.9% during the third quarter. Cooke & Bieler LP now owns 603,877 shares of the medical research company’s stock worth $94,483,000 after buying an additional 5,100 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Evercore raised their price objective on Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Argus set a $200.00 price target on Charles River Laboratories International in a research note on Monday, November 17th. TD Cowen restated a “buy” rating on shares of Charles River Laboratories International in a report on Thursday, January 22nd. Finally, Citigroup raised their price objective on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a report on Friday, January 16th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Charles River Laboratories International has an average rating of “Moderate Buy” and an average price target of $209.46.

Charles River Laboratories International Trading Down 2.4%

NYSE CRL opened at $181.16 on Wednesday. The firm has a market capitalization of $8.92 billion, a PE ratio of -116.13, a price-to-earnings-growth ratio of 5.57 and a beta of 1.63. The business’s 50-day moving average price is $204.63 and its two-hundred day moving average price is $180.05. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.